Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

Thomas Mcfall PhD
Assistant Professor
Department of Biochemistry

OFFICE ADDRESS:
Clinical Cancer Center
9200 W Wisconsin Ave
Milwaukee, WI 53226

EDUCATION:
09/01/2012 - 12/01/2017 PhD, Wayne State University, Detroit, MI
American Cancer Society Mentor: Tony Hunter PhD
Analysis of the role of nuclear receptors in the progression of cancer.
B.S. ; Advisor: Robert Winn Ph.D.
Cancer therapy has entered a new realm where systems pharmacology is leveraged to exploit selective, I have provided biological expertise and leadership to identify novel pharmacological inhibitors of Werner syndrome helicase (WRN). Inhibition of WRN in cancer cells that are microsatellite instabilit, leads to cell cycle arrest and death. Moreover, cells that are microsatellite
- 2020 Collaborator 2020-Present
Contributed to studies examining the role of MGMT expression and the resistance to Temozolomide in G
Dissertation: Mechanism of Hormonal Regulation of Invasiveness and Metastasis of Luminal Breast Canc
Donald W. Maine College of Business, Davenport 2010-2012 MBA/Hospital Administration
Donald W. Maine College of Business, Davenport Grand Rapids, MI 2010-2012
I am interested in experimental-systems approaches that enable mechanism-based inference in genomic
Ideaya Biosciences South San Francisco CA
In collaboration with Shumei Kato MD and Razelle Kurzrock MD (Moore's Cancer Center), we have investigated a unique scenario where a patient with estrogen receptor positive (ER) ovarian cancer harboring a mutant-KRAS was resistant to MEK inhibitor and Tamoxifen, however when treatment strategy was changed to MEK inhibitor and aromatase inhibitor the patient responded and continues to respond to this day. A mechanism for this finding is unknown. I have worked, and the estradiol-dependent ER
Initiation of research collaborations between for-profit and 501(c)3 organizations in support of bas, I developed a business strategy to develop a 501(c)3 organization within a university laboratory. Phase 1 of the plan recruited donors with the incentive of tax-deductible gifts. Upon the establishmen, (Phase 2) collaborations were built with for-profit hospitals and their neurosurgery departments. This unique strategy is an example of sustainable cashflow supporting the Upper Michigan Brain Tumor C
MAPK signaling cross talk with apo-estrogen receptor
MBA.
Masters Researcher; Advisor: Robert Winn Ph.D.
McFall, T., Trogdon, M.
McFall, T. and Stites EC. Redefining the relationship between colorectal cancer, RAS mutations, and the response to EGFR inhib
McFall T, Diedrich JK, Mengistu M, Littlechild SL
McFall T, Diedrich JK, Mengistu M, Littlechild SL
McFall T, McKnight B, Rosati R, Kim S
McFall T, Schomburg NK, Rossman KL, Stites EC. Discernment between
McFall T, Schomburg NK, Rossman KL, Stites EC. Discernment between
McFall T, Stites EC. A mechanism for the response of KRASG13D expressing colorectal cancers to EGFR inhibitors. Molecular & Cellular Oncology. 2020 Jan 12:1701914.
Mendiratta, G., McFall, T.
Moreover, as a professional collaborator I have developed a relationship with the physicist Dr. Mendiratta, at the Salk institute. We have utilized mathematical investigations to find that paradoxical activation (PA) by RAF inhibitors can result from a dynamical equilibrium between autoinhibited and non-aut, along with the RAF inhibitor s
My primary research interests focus on longstanding problems and controversies in observed clinical, yet these clinical guidelines are a result of an evolution of clinical practices and remain absent of the mechanistic underpinnings. My graduate years were focused on the role of progesterone utilizin, not limited to but including, estrogen receptor signaling an
Northern Michigan University Marquette, MI 2004-2008
Northern Michigan University Marquette, MI 2010-2012
PUBLICATIONS/ PREPRINTS
Patki M, McFall T (Equal Contributor), Rosati R, Huang Y
Ph.D. Cancer Biology
Ph.D. Candidate; Advisor: Manohar Ratnam Ph.D.
Postdoctoral fellow: Cancer Biology and Systems Pharmacology
Postdoctoral fellow; Advisor: Ed Stites MD/PhD 2017- Present
Progesterone receptor biology. As a graduate student I studied the role of the progesterone receptor, it was thought that the long isoform (PR-B) was mediating this effect, independent of estrogen action. These studies clarified the role of low hormone levels on breast cancer invasiveness, and event that is observed in
RAS signaling. As a trainee in the Stites lab I have focused on resolving a controversy surrounding, patients with an activating RAS mutation are not eligible for EGFR inhibitor therapy. In a retrospective study of clinical trial data, investigators found patients harboring a G13D mutation were sensitive to the EGFR inhibitor Cetuximab. This work has been recapitulated in both cell line and mouse models, however
RESEARCH EXPERIENCE
Research Interest and Approach
Role of ganciclovir in treating glioblastoma multiforme. Most humans carry a latent human cytomegalo, patients with glioblastoma multiforme have increased incidence of active virus in tumor tissues. We investigated the plausible role for Ganciclovir (HCMV anti-viral) as a treatment in the in vitro set
Rosati R, Polin L, Ducker C, Li J
Salk Institute for Biological Studies La Jolla CA
Salk Institute for Biological Studies La Jolla CA
Salk Institute for Biological Studies 2017-2020
Selected Publications
Senior Scientist/ Lead Biologist 2020-Present
Systems Pharmacology for synthetic lethal targets.
Systems Pharmacology to determine MAPK Dependencies
Systems Pharmacology. As a professional collaborator, I maintain a close relationship with my former post-doc mentor Ed Sites. Together, we have embarked to elucidate the role of biophysical parameters of RAS and MAPK-related proteins to refine the definition and characterization of molecular biomarkers. We have recently reported (Scie, is its ability to bind to the
Systems pharmacology approach to treating cancer.
Targeting ELK1/AR tethering to inhibit prostate cancer cell growth. As a graduate student I supporte, and developed a drug screen to identify a small molecule that could block this interaction. We were able to design several small molecules, which has led to a phase 1 clinical trial. This work had led to three publications and a clinical trial.
The role of glucocorticoid receptor alpha in lung cancer treatment strategies. As a student I acted, we have been able to show long term Dexamethasone treatment as a possible palliative care can cause decreased tumor burden, and increase cellular senescence in GR-alpha high tumors. This work has led to two publications (Scientific Reports and Journal of Thoracic Oncology) and has also led to the initiation of two clinical
Wayne State University Cancer Biology Graduate Program Detroit, MI 2012-2017
Wayne State University/ Barbara Ann Karmanos Cancer Institute 2012-2017

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
09/01/2017 - 06/01/2020 Postdoc, IBL, Salk Institute for Biological Studies, 10010 N torrey Pines, La Jolla, CA

FACULTY APPOINTMENTS:
08/01/2021 - Present Assistant Professor, Biochemistry, MCW